XML 74 R46.htm IDEA: XBRL DOCUMENT
v3.23.1

Commitments and Contingencies - Additional Information (Details) - USD ($) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Feb. 28, 2021 | Dec. 31, 2020 | Nov. 30, 2018 | Dec. 31, 2022
Amended Patent And Technology License Agreement |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Payments due related to milestones |  |  |  | $ 0
Patent And Technology License Agreement |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Term of agreement |  | 20 years |  |
Combined milestone payment maximum |  | $ 112,000,000 |  |
Payments due related to milestones |  |  |  | $ 0
Percentage of royalty description |  |  |  | There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by fifty percent (50%).
Claim expiration term |  | 10 years |  |
Regeneron |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Term of agreement | 5 years |  |  |
THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Term of agreement |  | 20 years |  |
Combined milestone payment maximum |  | $ 112,000,000 |  |
Minimum [Member] | Patent And Technology License Agreement |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Milestone payment |  | $ 1,000,000 |  |
Minimum [Member] | Patent And Technology License Agreement | Net sales up to $1,000,000,000 |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Rate of royalties on net sales |  | 2.00% |  |
Minimum [Member] | Patent And Technology License Agreement | Net sales above $1,000,000,000 |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Rate of royalties on net sales |  | 2.50% |  |
Minimum [Member] | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Milestone payment |  | $ 1,000,000 |  |
Minimum [Member] | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales up to $1,000,000,000 |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Rate of royalties on net sales |  |  | 2.00% |
Minimum [Member] | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales above $1,000,000,000 |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Rate of royalties on net sales |  | 2.50% |  |
Maximum | Patent And Technology License Agreement |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Milestone payment |  | $ 50,000,000 |  |
Maximum | Patent And Technology License Agreement | Net sales up to $1,000,000,000 |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Rate of royalties on net sales |  | 4.00% |  |
Maximum | Patent And Technology License Agreement | Net sales above $1,000,000,000 |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Rate of royalties on net sales |  | 5.00% |  |
Maximum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Milestone payment |  | $ 50,000,000 |  |
Maximum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales up to $1,000,000,000 |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Rate of royalties on net sales |  |  | 4.00% |
Maximum | THIO Therapeutics, Inc. | Amended Patent And Technology License Agreement | Net sales above $1,000,000,000 |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Rate of royalties on net sales |  | 5.00% |  |
Maximum | University Of Texas Southwestern | Patent And Technology License Agreement | Net sales above $1,000,000,000 |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Royalty payments on net sales |  | $ 1,000,000,000 |  |

X
- Definition Claim expiration term. + References No definition available. + Details
Name: | maia_ClaimExpirationTerm
Namespace Prefix: | maia_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Combined milestone payments maximum. + References No definition available. + Details
Name: | maia_CombinedMilestonePaymentsMaximum
Namespace Prefix: | maia_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | maia_MilestonePayment
Namespace Prefix: | maia_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments due related to milestones. + References No definition available. + Details
Name: | maia_PaymentsDueRelatedToMilestones
Namespace Prefix: | maia_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of royalty payments on net sales. + References No definition available. + Details
Name: | maia_PercentageOfRoyaltyPaymentsOnNetSales
Namespace Prefix: | maia_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty payments on net sales description. + References No definition available. + Details
Name: | maia_PercentageOfRoyaltyPaymentsOnNetSalesDescription
Namespace Prefix: | maia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty payments on net sales. + References No definition available. + Details
Name: | maia_RoyaltyPaymentsOnNetSales
Namespace Prefix: | maia_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Term of agreement. + References No definition available. + Details
Name: | maia_TermOfAgreement
Namespace Prefix: | maia_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=maia_AmendedPatentAndTechnologyLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=maia_PatentAndTechnologyLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=maia_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_THIOTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesUptoOneBillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=maia_NetSalesAboveOneBillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=maia_UniversityOfTexasSouthwesternMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |